Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5Ag85A Aerosol TB Vaccine Safety and Immunogenicity
NCT02337270Phase 1Completed
- Sponsor
- McMaster University
- Start
- Sep 2017
- Primary completion
- Sep 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ad5Ag85A in Tuberculosis (TB) (3 arms), sponsored by McMaster University. Primary endpoint: Number of participants reporting adverse events at 24 weeks. Started Sep 2017; status: completed.
02
Drugs
Ad5Ag85A
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02337270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337270.